WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year, multi-million dollar enterprise license and services agreement with Novo Nordisk, expanding the existing relationship between the two companies. Novo Nordisk plans to use Phase Forward’s InForm™ electronic data capture (EDC) product as the default data capture system across all clinical trial phases, from Phases I through IV.
